Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
19 mars 2018 06h35 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 19, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate...
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
14 mars 2018 07h45 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for...
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
14 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or...
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
13 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah Combination trial expands...
First Comprehensive Clinical Site Initiation Benchmark, Developed by Tufts Center for the Study of Drug Development, Finds Study Startup Is Lengthy and Inefficient
07 mars 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- The clinical site initiation process—time needed to identify and select sites and begin studies—takes an average of nearly eight months, longer than it did...
Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference
07 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30th...
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
28 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...
Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period
22 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Subscription period expected to end on March 2, 2018 at 5:00 PM ET NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"),...
Cognoa Hits Major Milestone Towards First AI-Based Autism Diagnostic
21 févr. 2018 09h04 HE
|
Cognoa
PALO ALTO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Cognoa, a company offering an AI-based platform for pediatric behavioral health diagnostics and digital therapeutics, announces that the U.S....
Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
20 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
Actimab-MDS to be featured in a Product Theater on February 21st Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of...